Company intelligence / Profile preview

Susonity

Chuo-ku, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Susonity is a Japanese biotechnology joint venture established in 2022 by Nxera Pharma (formerly Sosei Heptares) and Kowa Company. The entity was created specifically to develop and commercialize a portfolio of novel G protein-coupled receptor (GPCR) agonists within the Japanese market. Its primary asset is HTL0048141, a first-in-class selective GPR52 agonist currently in clinical development for the treatment of schizophrenia. By combining Nxera's structure-based drug design expertise with Kowa's commercial strength in Japan, Susonity aims to address significant unmet needs in psychiatric and neurological disorders.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Nxera PharmaKowa Company

Beyond the preview

Go deeper on Susonity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Susonity.

Explore the full profile